加味六君子汤联合TP方案治疗肺脾气虚型非小细胞肺癌的临床疗效观察

发布时间：2018-04-16 09:30

本文选题：加味六君子汤 + 非小细胞肺癌　；参考：《黑龙江中医药大学》2017年硕士论文

【摘要】：目的:通过加味六君子汤联合TP方案及单独TP方案对非小细胞肺癌治疗的临床疗效对比观察,探讨加味六君子汤的治疗作用。方法:收集2016年1月—2017年1月期间在黑龙江中医药大学附属第一医院和哈尔滨医科大学附属肿瘤医院就诊的原发性非小细胞肺癌(NSCLC)患者为观察对象,符合纳入标准,且中医辨证为肺脾气虚型者60例。对照组及治疗组各30例。所有患者均接受常规化疗治疗,若出现副反应采取针对性措施进行治疗。治疗组除了接受化疗治疗之外,还需口服加味六君子汤,服药时间从化疗前三天持续到停止化疗后的一周内。在治疗之前记录患者病理分型,对其进行TNM国际分期、卡氏评分、中医证候评价。结束治疗后观察疗效,再次进行卡氏评分以及中医证候评价。结果:1.在改善中医证候积分方面,治疗组优于对照组,组间对比具有显著性差异(P0.05)。2.在提高卡氏评分方面,治疗组优于对照组,组间对比具有显著性差异(P0.05)。3.在稳定瘤体方面,两组患者经治疗后均无CR病例,治疗组与对照组的有效率均为6.7%,治疗组稳定率为83.33%,高于对照组的76.67%,两组间比较无统计学意义(P0.05),但治疗组在稳定瘤体方面略有优势。4.在降低肿瘤标记物CEA、CY211水平方面,两组治疗后相比较,无显著意义(P0.05),但是治疗组较对照组下降明显。5.在不良反应方面,两组均未见明显的毒副反应。结论:1.加味六君子汤联合TP方案可以降低非小细胞肺癌患者的中医证候积分,提高卡氏评分,提高生活质量;2.加味六君子汤联合TP方案具有稳定瘤体的作用;3.加味六君子汤联合TP方案可以降低肿瘤标记物CEA、CY211水平;4.加味六君子汤联合TP方案不良反应轻微,安全可靠。
[Abstract]:Objective: To compare the clinical efficacy observation of the treatment of non-small cell lung cancer by Modified Decoction of six noble drugs combined with TP regimen and TP regimen alone, to investigate the therapeutic effects of Modified Decoction of six noble drugs. Methods: from January 2016 to January 2017 in the First Affiliated Hospital of Heilongjiang University Of Chinese Medicine and Cancer Hospital Affiliated to Harbin Medical University for treatment of primary non-small cell lung cancer (NSCLC) patients the object, in accordance with the inclusion criteria, and TCM syndrome differentiation of lung and spleen deficiency in 60 cases. The control group and the treatment group with 30 cases in each group. All patients received conventional chemotherapy treatment, if adverse reactions take targeted treatment measures. The treatment group in addition to chemotherapy treatment, also need oral modified decoction of six noble drugs, medication time from three days before chemotherapy to stop after chemotherapy within a week. The pathological type were recorded before treatment, the TNM of the international stage, calmetii Score, TCM syndrome efficacy evaluation. After the end of treatment, again and Karnofsky score of TCM Syndrome Evaluation. Results: 1. points in improving TCM syndrome, the treatment group than the control group, the comparison between the two groups had significant difference (P0.05) of.2. in improving the Karnofsky score, the treatment group than the control group the comparison between the two groups, with significant difference (P0.05) of.3. on the stability of the tumor, two groups of patients after treatment, there were no CR cases, the effective rate of the treatment group and the control group was 6.7%, the treatment group rate of 83.33%, higher than 76.67% in the control group, there was no significant difference between the two groups (P0.05), but the treatment group in the stable tumor advantage of.4. in reducing tumor markers CEA, CY211 level, the two groups after treatment compared with no significant difference (P0.05), but the treatment group decreased significantly than the control group.5. in terms of adverse reactions, two groups were no obvious adverse reaction Conclusion: 1.. Modified Decoction of six noble drugs combined with TP regimen can reduce the TCM syndromes in patients with small cell lung cancer, improve Karnofsky score, improve the quality of life; 2. Modified Decoction of six noble drugs combined with TP regimen has a stable tumor effect; 3. Modified Decoction of six noble drugs combined with TP chemotherapy can reduce tumor markers CEA the level of CY211; the adverse reactions of the 4. Modified Decoction of six noble drugs combined with TP regimen in mild, safe and reliable.

【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2

【参考文献】